| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
7.62(B) |
| Last
Volume: |
2,042,374 |
Avg
Vol: |
1,949,589 |
| 52
Week Range: |
$43.45 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
165,194 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,160,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
60 |
100 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-03-10 |
4 |
AS |
$6.05 |
$18,398 |
D/D |
(3,041) |
225,129 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-03-10 |
4 |
AS |
$6.05 |
$13,159 |
D/D |
(2,175) |
16,326 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-03-10 |
4 |
AS |
$6.05 |
$24,454 |
D/D |
(4,042) |
269,168 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,425 |
228,170 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,025 |
18,501 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,400 |
712,307 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,275 |
273,210 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2016-03-08 |
4 |
B |
$6.43 |
$32,150 |
D/D |
5,000 |
21,459 |
2.39 |
- |
|
| Napier Katherine S |
Director |
– • – |
2016-03-03 |
4 |
B |
$5.38 |
$20,297 |
D/D |
3,775 |
91,000 |
2.39 |
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-03-01 |
4 |
AB |
$5.00 |
$250,000 |
D/D |
50,000 |
687,907 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-02-26 |
4 |
AS |
$5.81 |
$40,060 |
D/D |
(6,895) |
637,907 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-02-25 |
4 |
AS |
$5.52 |
$16,543 |
D/D |
(2,997) |
219,745 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-02-25 |
4 |
AS |
$5.52 |
$22,626 |
D/D |
(4,099) |
261,935 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,250 |
222,742 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,000 |
266,034 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
644,802 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-02-23 |
4 |
AS |
$6.39 |
$15,406 |
D/D |
(2,411) |
214,492 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-02-23 |
4 |
AS |
$6.39 |
$43,874 |
D/D |
(6,866) |
625,302 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-02-23 |
4 |
AS |
$6.39 |
$16,333 |
D/D |
(2,556) |
255,034 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,225 |
216,903 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,375 |
632,168 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,225 |
257,590 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-01-21 |
4 |
OE |
$0.83 |
$53,950 |
D/D |
65,000 |
250,365 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-01-11 |
4 |
OE |
$0.83 |
$220,717 |
D/D |
265,924 |
612,973 |
|
- |
|
| Thompson David |
Director |
– • – |
2016-01-11 |
4 |
B |
$6.99 |
$104,850 |
D/D |
15,000 |
110,213 |
2.39 |
- |
|
777 Records found
|
|
Page 27 of 32 |
|
|
0.04 (0.09%) 
